KMR Group
There is much being written on the importance of emerging markets for clinical research, but it is difficult to accurately gauge how much activity is actually taking place, and, more specifically, in what disease areas. In this analysis we set forth answers to these questions with respect to one region, Asia, relying on the KMR Group clinical dataset1 as a resource.
The global assessment reveals the primary source of subjects for interventional clinical trials continues to be North America and Western Europe at more than two thirds. Emerging markets2 constitute 29% of patients in recent studies; Asia (excluding Japan) alone makes up 6%. Within Asia, the top country is China, followed by India and South Korea.
The most popular disease areas within Asia are: Diabetes, Thrombosis, Coronary Disease, and Lung Cancer (non-small cell). When viewing where subjects are randomized for each of these, China does not always rank first. More than 40% of Diabetes patients are from India, for example, as are almost half of all Coronary patients. Taiwan contributes 13% of Lung Cancer patients but China ranks highest at 40%.
As companies continue to pursue clinical research in emerging markets, it can be helpful to understand the environment in more quantitative terms, such as what type of research is being performed, to what extent and in which disease areas. In addition, other factors such as cost, regulatory environment, patient access, and performance, should all be weighed in the equation.
For a more thorough evaluation of emerging markets, including performance information such as recruitment rates and site performance statistics, companies can refer to the KMR Group Emerging Markets Performance Study; for site based performance statistics in emerging markets, there is Site Scorecard. For determining where to best to place studies for particular diseases, consult the Best Places for Clinical Research series.
– KMR Group, https://kmrgroup.com
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.